Bacteria-derived DNA fragment in peritoneal dialysis effluent as a predictor of relapsing peritonitis

腹膜透析液中细菌来源的DNA片段可作为复发性腹膜炎的预测因子

阅读:1

Abstract

BACKGROUND AND OBJECTIVES: Relapsing and recurrent peritonitis episodes are important causes of treatment failure in patients undergoing peritoneal dialysis (PD). This study explored whether the level of bacteria-derived DNA fragment in PD effluent predicts the development of relapsing or recurrent peritonitis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included 143 patients with PD peritonitis in a dialysis unit between September 2010 and December 2011. Every 5 days until antibiotic treatment ended, PD effluent was collected to determine bacteria-derived DNA fragment level, which is represented by the number of PCR cycles at which bacterial DNA could be detected. Patients were followed for the development of relapsing or recurrent peritonitis. RESULTS: Thirty-nine patients were excluded because of immediate treatment failure or incorrect diagnosis. Of the other 104 patients, 15 (14.4%) developed relapsing peritonitis, 3 (2.9%) had recurrent peritonitis, and 5 (4.8%) had repeat episodes. Patients with relapsing or recurrent peritonitis episodes had significantly higher levels of bacterial DNA fragment in PD effluent than those without relapsing or recurrence, both 5 days before (31.9 ± 3.4 versus 34.3 ± 3.0 cycles; P=0.002) and on the day of (32.3 ± 2.6 versus 34.1 ± 1.7 cycles; P<0.001) completion of antibiotics. When bacterial DNA fragment detectable by 34 PCR cycles 5 days before the completion of antibiotics is used as the cutoff, it has a sensitivity of 88.9% and specificity of 60.5% for the prediction of relapsing or recurrent peritonitis. CONCLUSIONS: Bacterial DNA fragment levels in PD effluent are significantly higher, both 5 days before and on the date of completion of antibiotics, among patients who subsequently develop relapsing or recurrent peritonitis than among those cured by antibiotics. Further studies are needed to validate these results and confirm the clinical utility of dialysate bacterial DNA fragment level.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。